Company intelligence / Profile preview

GeneProof

Ownership: Private
Employees: ~100
Development stage: Commercial

Overview

GeneProof develops and markets over seventy-five advanced molecular diagnostic products for the detection of serious infectious agents and genetic diseases. Their portfolio includes real-time PCR kits for viral/bacterial pathogen detection in clinical samples—especially relevant in immunocompromised or transplant patients—and genetic disease screening. The company exports to more than seventy-five countries worldwide. In clinical use globally; not a drug developer so no traditional clinical trial results apply.

Therapeutic areas: OncologyRare DiseasesInfectious Diseases
Modalities: PCR-based diagnosticsReal-time PCRImmunoassay testingAutomated laboratory instrumentation
Industry: Molecular Diagnostics

Partnerships

Merged with ALPCO to form a global leader in diagnosticsdistribution partnerships worldwide

Beyond the preview

Go deeper on GeneProof.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GeneProof.

Explore the full profile